ALTIUM
18.2.2020 15:32:10 CET | Business Wire | Press release
EMBEDDED WORLD — Today Altium, a global leader in PCB design software, announced the launch of a new cloud-based application that redefines the way that printed circuit board designs are shared between designers, part suppliers, and manufacturers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200218005188/en/
The A365 Viewer, powered by the Altium 365 cloud platform, is a brand new, and innovative way to view and share electronic designs through a browser on any web-enabled desktop, phone or tablet. Schematics, PCB layout, and 3D visualization provide an interactive eCAD experience with no downloads or installations required. The A365 Viewer is part of Altium’s cloud strategy and newly launched Altium 365 cloud platform.
Simplicity is the Ultimate Sophistication
Until now, designers have been forced to share their PCB designs through PDFs or static images. With the new A365 Viewer, an interactive experience is created that retains all of the key relevant information that's typically lost when sharing static files. For example, the A365 Viewer allows users to search for, select, cross-probe and inspect components and nets while moving seamlessly between schematic, PCB and 3D views of their board.
Using the A365 Viewer requires no CAD tools or experience. The A365 Viewer is designed to work with multiple eCAD formats, currently supporting Autodesk® Eagle™ and Altium Designer™. Other popular PCB design software formats will be supported in the near future.
Easily Embedded on Your Website
Anyone can easily embed the viewer on their website, free of charge, by visiting https://www.altium.com/viewer/ . As an example, a well-known developer of electronics hardware and software kits, Arduino, is helping engineers and makers to easily and quickly visualize the PCB designs and assemblies available in their product kits, by embedding the A365 Viewer on the Arduino website .
"Adding the Altium 365 Viewer has significantly enhanced the user experience when navigating the product documentation in our website. Now Arduino users can freely browse schematics, PCB layout and even 3D models of the Arduino boards and modules online, without the need to download or install anything additional. The capability of being CAD-agnostic will shorty allow Arduino to add the online design viewer to every product page, including the ones designed in Autodesk Eagle. " - Fabio Violante, CEO, Arduino
Built-in Design IP Protection
The A365 Viewer protects the IP rights of design owners while retaining the CAD design details via a new process called Published Design Impression (PDI). The Viewer processes the design source files to create a Published Design Impression, or PDI. The PDI is a CAD-aware, perishable snapshot of the design that captures limited information such as components, net connectivity and basic geometrics, excluding design primitive data that would be required to fully comprehend and author changes to the design.
The design sources are discarded immediately after being used solely for the purpose of creating a PDI. The design is available for the duration of the user’s browser session and is automatically removed when the browser tab is closed.
Altium is demonstrating its A365 Viewer at the Embedded World 2020 trade show, Hall 4 stand 371, taking place at the Nuremberg Exhibition Center on February 25-27. To learn more visit: https://www.altium.com/viewer/
ABOUT ALTIUM
Altium LLC (ASX:ALU ), a global software company headquartered in San Diego, Calif., is accelerating the pace of innovation through electronics. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.
The growing demand for smart and connected products is driving advancements in electronics technology. Design trends are demonstrating the need for minimizing power, reducing package size and energy consumption, and prioritizing high-speed design. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers, from idea to board. Users are at the center of Altium’s R&D and business operations. With its unique Business-to-User approach, Altium is focused on developing software that is easy to use and implement, with solutions that enable innovation and deliver industry-leading user productivity.
Products include Altium Designer®, Altium Concord Pro™, Altium 365®, Altium NEXUS®, CircuitMaker®, CircuitStudio®, Octopart®, and TASKING®. To learn more about Altium, visit www.altium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005188/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom